Pipeline

R&D is the core of our innovation. Sinotau has expanded product portfolio into oncology, cardiology and neurology with a diverse and competitive range of radiopharmaceutical pipelines. All with the mission of inventing radiopharmaceuticals for lives.

Diagnostic
Therapeutic

Cardiovascular disease

Pipeline
Pre-clinical
During clinical
NDA(ANDA)

XTR003

Detection of myocardial viability/metabolism

XTR004

Detection of myocardial ischemia

Neurodegenerative disease

Pipeline
Pre-clinical
During clinical
NDA(ANDA)

XTR006

AD

Cancer

Pipeline
Pre-clinical
During clinical
NDA(ANDA)

XTR008

Neuroendocrine tumor

XTR010

Prostate cancer

XTR012

Bone metastases from prostate cancer

XTR015

NETs

XTR016

Advanced solid tumors

XTR017

Advanced solid tumors

XTR020

Prostate cancer

XTR021

mCRPC

XTR022

mCRPC that have failed 177Lu-PSMA treatment;mCRPC (≥2L)

XTR024

G1/G2 GEP-NETs that have failed 177Lu SSTR treatment/G3 NETs/NECs;ES-SCLC

XTR025

Glioblastoma